Ensign Peak Advisors Inc Cuts Stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Ensign Peak Advisors Inc trimmed its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 3.4% during the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 128,711 shares of the biopharmaceutical company’s stock after selling 4,471 shares during the quarter. Ensign Peak Advisors Inc owned 0.12% of Regeneron Pharmaceuticals worth $135,279,000 at the end of the most recent quarter.

Several other large investors have also recently added to or reduced their stakes in REGN. Vanguard Group Inc. grew its position in Regeneron Pharmaceuticals by 1.0% during the first quarter. Vanguard Group Inc. now owns 8,930,241 shares of the biopharmaceutical company’s stock worth $8,595,268,000 after buying an additional 91,956 shares during the period. Capital World Investors increased its position in shares of Regeneron Pharmaceuticals by 0.5% in the fourth quarter. Capital World Investors now owns 5,130,485 shares of the biopharmaceutical company’s stock valued at $4,506,071,000 after buying an additional 23,146 shares in the last quarter. Capital International Investors raised its stake in shares of Regeneron Pharmaceuticals by 7.3% during the 1st quarter. Capital International Investors now owns 3,129,010 shares of the biopharmaceutical company’s stock worth $3,011,640,000 after buying an additional 213,038 shares during the last quarter. Putnam Investments LLC boosted its position in shares of Regeneron Pharmaceuticals by 2.1% in the 4th quarter. Putnam Investments LLC now owns 1,210,735 shares of the biopharmaceutical company’s stock worth $1,063,377,000 after buying an additional 24,329 shares in the last quarter. Finally, Price T Rowe Associates Inc. MD grew its stake in Regeneron Pharmaceuticals by 25.7% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 902,613 shares of the biopharmaceutical company’s stock valued at $868,757,000 after acquiring an additional 184,561 shares during the last quarter. 83.31% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

REGN has been the subject of several recent research reports. Guggenheim raised their price target on Regeneron Pharmaceuticals from $1,180.00 to $1,300.00 and gave the stock a “buy” rating in a research report on Friday, August 2nd. Argus raised their price objective on Regeneron Pharmaceuticals from $1,060.00 to $1,170.00 and gave the stock a “buy” rating in a report on Tuesday, June 25th. Canaccord Genuity Group reiterated a “buy” rating and set a $1,152.00 target price on shares of Regeneron Pharmaceuticals in a research report on Thursday, June 27th. StockNews.com raised shares of Regeneron Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Tuesday, September 10th. Finally, Wells Fargo & Company increased their target price on Regeneron Pharmaceuticals from $1,125.00 to $1,200.00 and gave the stock an “overweight” rating in a research report on Friday, August 2nd. One investment analyst has rated the stock with a sell rating, two have given a hold rating, sixteen have assigned a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $1,111.30.

Regeneron Pharmaceuticals Trading Down 0.4 %

Shares of REGN stock opened at $1,145.03 on Friday. Regeneron Pharmaceuticals, Inc. has a 1 year low of $769.19 and a 1 year high of $1,211.20. The firm has a market capitalization of $126.17 billion, a PE ratio of 33.83, a price-to-earnings-growth ratio of 3.93 and a beta of 0.12. The stock has a fifty day moving average of $1,131.75 and a two-hundred day moving average of $1,031.74. The company has a debt-to-equity ratio of 0.10, a quick ratio of 4.62 and a current ratio of 5.44.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings results on Thursday, August 1st. The biopharmaceutical company reported $11.56 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $8.93 by $2.63. Regeneron Pharmaceuticals had a return on equity of 16.80% and a net margin of 32.04%. The firm had revenue of $3.55 billion during the quarter, compared to analyst estimates of $3.38 billion. During the same period last year, the company posted $8.79 EPS. The firm’s quarterly revenue was up 12.3% on a year-over-year basis. As a group, research analysts expect that Regeneron Pharmaceuticals, Inc. will post 37.8 EPS for the current year.

Insider Transactions at Regeneron Pharmaceuticals

In related news, CFO Christopher R. Fenimore sold 5,680 shares of Regeneron Pharmaceuticals stock in a transaction dated Wednesday, August 28th. The stock was sold at an average price of $1,205.33, for a total value of $6,846,274.40. Following the transaction, the chief financial officer now owns 15,305 shares of the company’s stock, valued at approximately $18,447,575.65. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. In other news, Director Arthur F. Ryan sold 100 shares of the business’s stock in a transaction on Monday, July 1st. The shares were sold at an average price of $1,059.24, for a total transaction of $105,924.00. Following the transaction, the director now directly owns 17,882 shares in the company, valued at approximately $18,941,329.68. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, CFO Christopher R. Fenimore sold 5,680 shares of Regeneron Pharmaceuticals stock in a transaction on Wednesday, August 28th. The shares were sold at an average price of $1,205.33, for a total value of $6,846,274.40. Following the sale, the chief financial officer now directly owns 15,305 shares of the company’s stock, valued at approximately $18,447,575.65. The disclosure for this sale can be found here. Insiders have sold 10,026 shares of company stock valued at $11,498,705 in the last quarter. Insiders own 7.48% of the company’s stock.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.